top of page

iQ-007 Zebrafish Screening Reveals Positive Results in Other Neurodegenerative Diseases

Princeton, NJ, June 21 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech  company dedicated to the development of new epilepsy and pain management therapeutics, is proud to announce that its lead asset iQ-007, has shown positive results in a zebrafish screening for a series of neurodegenerative diseases.


iQ-007 is a positive allosteric modulator of the EAAT2 transporter and represents a novel approach to treat neurodegenerative diseases.  Based on the positive results of iQ-007 for epilepsy and the successful completion of the ETSP program, iQure decided to explore the general mechanism of action of iQ-007 in other neurodegenerative diseases. Over the last few months, iQ-007 was tested in a series of in vivo zebrafish models of many high medical need neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease. iQ-007 produced statistically significant effects in all models, matching, or in some cases exceeding positive control results, underpinning the importance of the role of EAAT2 in neurodegenerative diseases. “This excellent set of results supports iQ-007 as a Platform Therapeutic with the potential for helping patients who are suffering from these debilitating diseases.” said Pawel Zolnierczyk, iQure CEO. “We are looking forward to continuing to explore iQ-007’s clinical development potential and optimum market positioning.”

About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies.


For more information about supporting iQure’s initiatives, contact iQure CEO Pawel Zolnierczyk at

52 views0 comments

Recent Posts

See All


bottom of page